Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.

Gennaro Pagano <a class=“affiliation-link” title=“Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. Gennaro.Pagano@Roche.com.” href=“https://pubmed.ncb …